Review
2020 December
Volume : 8 Issue : S1


Treatment modalities for coronavirus disease 2019 (COVID-19)

Panduranga G

Pdf Page Numbers :- 106-111

Gautam Panduranga1,*

 

1Department of Internal Medicine, Krishna Institute of Medical Sciences, Minister Road, Secunderabad-500003, Telangana, India

 

*Corresponding author: Dr. Gautam Panduranga, MD., Consultant Physician, Department of Internal Medicine, Krishna Institute of Medical Sciences, Minister Road, Secunderabad-500003, Telangana, India. Email: gautampsetty@yahoo.com

 

Received 10 November 2020; Revised 21 November 2020; Accepted 26 November 2020; Published 30 November 2020

 

Citation: Panduranga G. Treatment modalities for coronavirus disease 2019 (COVID-19). J Med Sci Res. 2020; 8(S1):106-111. DOI: http://dx.doi.org/10.17727/JMSR.2020/8S1-13

 

Copyright: © 2020 Panduranga G. Published by KIMS Foundation and Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

View Full Text | PDF

Abstract

Management of coronavirus disease 2019 (COVID-19) infection is based on limited data and keeps changing rapidly as new clinical data emerge. Remdesivir has shown to reduce duration of hospital stay and has been approved for treatment. In RECOVERY trial, corticosteroids lowered 28-day mortality in patients requiring oxygen supplementation or mechanical ventilation. Convalescent plasma did not live up to its initial promise and is not the standard of care for treatment at present. There’s not enough evidence for use of Hydroxychloroquine, Interleukin-6 inhibitors and many other investigational drugs. Bamlanivimab, casirivimab- imdevimab combo, all monoclonal antibodies, have recently been approved for use in mild to moderate COVIID-19, when there’s a high risk of progression to severe disease. Treatment of COVID-19 depends on stage and severity of disease. Antiviral medications are likely to be most effective when used early. Later in the disease, anti-inflammatory medications, anticoagulants and immunomodulators may be more effective. The world is waiting and hoping for a safe and effective vaccine which can put an end to this worldwide pandemic.

 

Keywords: COVID-19; treatment; coronavirus disease; remdesivir; favipravir; hydroxychloroquine; COVID antibody therapies

Subscription